We designed in vitro experiments in this study to reduce and eliminate residual cancer cells maintained by treatment-induced adaptive reprogramming (Fig. 1a) using three ALK-rearranged lung cancer cell lines with different EML4-ALK variants (H3122, H2228, and A925L cells). This evidence concerns the gene ALK and lung carcinoma.